Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,029 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recombinant Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, HIVAC-1e
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
2
States / cities
Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

NCT00002126
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Filgrastim
Drug
Lead sponsor
Amgen
Industry
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Trastuzumab in Treating Patients With Prostate Cancer

NCT00003740
View directory record Official record
Conditions
Prostate Cancer
Interventions
trastuzumab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

NCT06112834
View directory record Official record
Conditions
Botulism
Interventions
rBV A/B
Biological
Lead sponsor
California Department of Public Health
Other
Eligibility
18 Years to 69 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Richmond, California • West Jefferson, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

NCT01426763
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CINRYZE with rHuPH20
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Treatment Program for Anemia in AIDS Patients

NCT00002022
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

NCT00000728
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

NCT03061201
View directory record Official record
Conditions
Hemophilia A
Interventions
SB-525 (PF-07055480)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
22
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

NCT00245245
View directory record Official record
Conditions
Hemophilia A
Interventions
recombinant porcine coagulation factor VIII (OBI-1)
Drug
Lead sponsor
Octagen Corporation
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Oct 27, 2026, 9:47 AM EDT
Terminated Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

NCT02781467
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
PNK-007, Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2)
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

NCT00004419
View directory record Official record
Conditions
Insulin Resistance, Hyperglycemia
Interventions
insulin-like growth factor I
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000757
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1992
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Results available

A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

NCT02910466
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

NCT02230566
View directory record Official record
Conditions
MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII
Interventions
UX003, Placebo
Drug · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Oakland, California • Orange, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

NCT00803972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rHuPH20, Insulin Human Injection, Insulin Lispro Injection
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

NCT03722472
View directory record Official record
Conditions
Pulmonary TB
Interventions
ID93 + GLA-SE
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

NCT00270478
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
Interventions
Erythropoietin and Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

NCT04224701
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 51 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 27, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Use of Activated Recombinant FVII in Spinal Surgery

NCT00102037
View directory record Official record
Conditions
Acquired Bleeding Disorder, Spinal Fusion
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 27, 2026, 9:47 AM EDT
Recruiting Phase 3 Interventional

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT05659381
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions
Cisplatin, No treatment
Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
59
States / cities
Duarte, California • La Jolla, California • Newport Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 9:47 AM EDT